Most people searching for a MAT provider are doing it under pressure: a crisis just passed, a family member is watching, or a window of motivation is open that won’t stay open long. Knowing the right questions to ask a MAT provider before that first appointment can be the difference between landing in a program that works for your life and dropping out of one that doesn’t.
Why These Questions Matter
According to SAMHSA’s 2022 National Survey on Drug Use and Health, approximately 4.1 million people with opioid use disorder received no treatment in the prior year. Of those who did start treatment, early dropout remains a pervasive problem: research published in the Journal of Substance Abuse Treatment found that between 30 and 50 percent of patients leave MAT programs within the first 90 days, often citing program inflexibility, cost surprises, or a mismatch between what was promised and what was delivered.
That dropout rate is not mostly about willpower. It is about fit. A program that doesn’t match your schedule, your insurance, your need for privacy, or your clinical needs will eventually lose you, regardless of how motivated you are when you walk through the door. The 12 questions below function as a practical interview guide, not a box-ticking exercise. Bring them to your first phone call. The answers will tell you more than any marketing language on a clinic’s website.
1. What Medications Do You Prescribe , and Why?
This is the first question because the answer reveals whether a clinic is practicing evidence-based medicine or running a one-medication operation that may not fit your situation.
A landmark 2021 study published in the New England Journal of Medicine confirmed what NIDA’s treatment guidelines have stated for years: methadone, buprenorphine, and naltrexone all reduce opioid use and overdose mortality, but they work through different mechanisms and suit different patients. Methadone is a full opioid agonist dispensed only through federally certified opioid treatment programs (OTPs), meaning daily clinic visits are required, at least initially. Buprenorphine is a partial agonist that can be prescribed in office-based settings by DEA-waivered clinicians, making it far more compatible with working and family life. Naltrexone (most commonly as extended-release injectable Vivitrol) is a full antagonist, meaning it blocks opioid receptors entirely, and it requires complete detoxification before induction.
What this means in practice: a clinic that only prescribes one of these medications is not necessarily a bad clinic, but you deserve an explanation of why their first-line recommendation fits your specific history, physiology, and lifestyle. If the prescriber cannot articulate that reasoning clearly in the first conversation, that is a meaningful data point.
The concrete action here: before the first appointment, verify whether the clinic’s prescriber holds a DEA buprenorphine prescribing authorization. Under the Consolidated Appropriations Act of 2023, the X-waiver requirement was eliminated, but not all prescribers actively prescribe buprenorphine. Confirm it directly.
2. Is This Program Outpatient, and How Flexible Is the Schedule?
A 2022 study in the Journal of Substance Abuse Treatment examined retention rates across outpatient and inpatient MAT settings and found that outpatient programs with flexible scheduling had significantly higher 6-month retention among employed adults and caregivers. The mechanism is not complicated: when treatment appointments require you to miss work, arrange childcare, or explain your absence to an employer, each visit becomes a logistical obstacle. Enough obstacles and the calculus shifts.
A rigid Monday-through-Friday, 9-to-5 appointment structure functionally disqualifies most working adults, parents of school-age children, and anyone with an unpredictable shift schedule. Outpatient care should bend toward your life, not the other way around. Programs that have adapted to this reality offer early morning slots, evening appointments, and telehealth follow-ups for stable patients. Programs that haven’t tend to serve a narrower population and retain them at lower rates.
Ask specifically: are early morning appointments available? Is there an evening option? Can established patients do telehealth check-ins? If the answer to all three is no, that program’s accessibility profile is not consistent with current evidence on retention. Understanding how to match a program’s structure to your actual schedule before you commit is one of the most underdiscussed parts of this decision.
3. Do You Accept My Insurance , and What Will I Actually Pay?
Knowing a clinic “takes insurance” is not the same as knowing what you will pay. These are two completely different questions.
The Mental Health Parity and Addiction Equity Act (MHPAEA) requires that insurance plans cover substance use disorder treatment at parity with medical and surgical benefits, but a 2023 KFF analysis found significant gaps in how that law is enforced, with many plans still imposing prior authorization requirements, step-therapy protocols, or visit limits that effectively restrict access. A clinic that accepts your insurer can still leave you with out-of-pocket costs that make sustained treatment financially unsustainable.
What to ask: does the clinic have a billing specialist who will verify your specific benefits before intake? What is the expected copay per visit for the first 90 days? Are lab tests, counseling, and prescriptions billed separately or bundled? The last question matters more than most patients realize. Some clinics bill each component of care through separate codes, which can result in three or four separate cost-sharing obligations per visit.
The practical step: ask the provider to run a full benefits verification before your intake appointment and request a written estimate. Any clinic serious about patient retention will do this routinely. A clinic that cannot or will not provide this information before you commit is making your financial exposure invisible by design.
4. What Does the Intake Process Look Like?
Speed of entry is one of the strongest predictors of whether someone actually starts treatment. A 2020 study in the Journal of Substance Abuse Treatment compared same-day and delayed induction protocols across multiple outpatient MAT sites. Patients who were inducted on the same day they presented for care were nearly twice as likely to still be in treatment at 30 days compared to those who waited more than 72 hours. The window between deciding to seek help and actually receiving a first dose is where most people fall out.
This is not a minor scheduling matter. It reflects the clinic’s understanding of how opioid use disorder works, including the compulsive nature of the disease, the fluctuating nature of motivation, and the fact that telling someone who is actively using to “come back on Thursday for an assessment” is a clinical error as much as an operational one.
Ask this question directly: how many days typically pass between first contact and the first prescription? If the answer is more than three days, ask what happens during that gap, whether there is any bridging support, and what percentage of people who schedule an intake appointment actually show up for it. A provider who has not thought carefully about this question has probably not thought carefully about retention.
5. Is Counseling Included, or Is This Medication Only?
SAMHSA defines MAT explicitly as the combination of FDA-approved medications with counseling and support services. That definition is not arbitrary. A 2019 Cochrane systematic review, drawing on data from over 100 clinical trials, found that patients receiving both medication and behavioral therapy had consistently better outcomes across measures including retention, illicit drug use, and quality of life than those receiving medication alone.
A prescription pad without a licensed counselor is not MAT by clinical definition. It is pharmacotherapy, which has real value but leaves a significant portion of the treatment model on the table. The behavioral component addresses the psychological and social dimensions of opioid use disorder: the triggers, the thought patterns, the relationships, the trauma. Medication stabilizes the neurological substrate. Counseling changes what happens in the context where use occurs.
Ask whether a licensed counselor or therapist is on staff at the clinic itself, not just available as a referral. Ask whether individual therapy sessions are included in the base program cost or billed separately. Ask how often you would meet with a counselor, not just a prescriber. Programs that integrate counseling into the standard care model tend to have stronger long-term outcomes than those that treat medication management and behavioral health as separate services.
6. How Do You Handle Dosing Adjustments and Side Effects?
A 2022 study in the Annals of Internal Medicine examined buprenorphine dosing variability across 1,400 patients in outpatient treatment and found that patients receiving individualized, flexible dosing had significantly higher retention rates than those on fixed-dose protocols. The clinical explanation is straightforward: opioid tolerance, metabolism, and treatment response vary substantially between individuals. A starting dose that stabilizes one patient may leave another with persistent cravings or intolerable side effects.
A one-size protocol is a warning sign. Good MAT prescribers treat dosing as an ongoing clinical conversation, not a checkbox on an intake form. The relevant questions: who makes dosing decisions, and do they have addiction medicine training? How quickly can a dose be adjusted if the current level is not working? What is the process for reporting a side effect between scheduled appointments, and is there a clinician available to respond promptly?
The action here is to ask the provider to describe, in concrete terms, the last time they adjusted a patient’s dose mid-cycle and how long that process took from the patient reporting a problem to a change being made. A provider who answers this question fluently is running a responsive clinical operation. A provider who deflects to policy language probably isn’t.
7. What Happens If I Relapse During Treatment?
NIDA’s clinical data is unambiguous on this point: relapse rates during the first year of MAT range from 40 to 60 percent, and relapse does not mean treatment failure. It means the chronic brain disorder known as opioid use disorder behaved like a chronic brain disorder. The clinical response to a relapse should be evaluation and adjustment, not punishment.
Programs that discharge patients for a single positive urine screen or episode of use operate outside the current evidence base and produce outcomes that reflect it. The research literature on relapse-punitive protocols consistently shows higher rates of treatment dropout, higher rates of overdose following dropout (due to tolerance loss), and no improvement in long-term abstinence compared to non-punitive programs. A 2021 analysis in JAMA Psychiatry examining outcomes across 12 outpatient MAT programs found that non-punitive relapse policies were among the strongest predictors of 12-month retention.
Ask the provider directly: what happens if a patient tests positive for opioids during treatment? Listen carefully for whether the first word in the response involves any variation of “discharge” or “dismissal.” A program grounded in current evidence will describe a clinical response: increased monitoring, counseling intensity, medication review, possibly a higher level of care. Programs that lead with consequences are telling you something important about their model.
8. Who Are the Clinicians, and What Are Their Credentials?
A 2023 HRSA workforce report estimated that the United States faces a shortage of more than 26,000 addiction medicine providers, with rural and suburban areas facing the sharpest gaps. That shortage has created a situation where clinics can operate legally with prescribers who have no specialized training in addiction medicine beyond what is required for a basic medical license.
A clinic can be licensed and operating within legal parameters without having a board-certified addiction medicine specialist on staff. The distinction matters. Board certification in addiction medicine through the American Board of Preventive Medicine (ABPM), or addiction psychiatry through the American Board of Psychiatry and Neurology (ABPN), requires dedicated training, supervised clinical hours, and rigorous examination. A general practitioner who completes the minimum requirements to prescribe buprenorphine is not the same as an addiction medicine specialist, even if both are technically qualified to write the prescription.
Ask specifically whether the prescribing physician holds board certification in addiction medicine or addiction psychiatry. Then verify it independently. Both the ABPM and ABPN maintain public directories of certified physicians. Staff credentials and clinical continuity have a direct relationship to patient outcomes, and the strongest programs make both transparent without being asked.
9. How Is My Privacy Protected?
Most people are aware of HIPAA. Fewer know that substance use disorder records are governed by a separate, stricter federal regulation: 42 CFR Part 2. Under this rule, SUD treatment records cannot be shared with other providers, insurers, or third parties without specific written patient consent, except in defined emergency situations. This is a higher standard of protection than standard medical records, and it exists because Congress recognized the distinct stigma and legal risks associated with opioid use disorder.
A 2021 study in the Journal of Substance Abuse Treatment examining stigma as a barrier to treatment-seeking found that fear of disclosure to employers, family members, or legal systems was one of the top three reported reasons people delayed or avoided MAT. Understanding that your records are protected under a separate federal law changes the risk calculus in a meaningful way.
Ask the clinic whether it operates under 42 CFR Part 2. Ask how records are shared with other providers involved in your care, and whether any information is disclosed to insurance companies beyond what is required for billing. Ask whether the clinic uses electronic health records integrated with hospital systems where your SUD history might be visible to providers outside the addiction treatment context. A clinic operating at a high standard will have clear answers and written policies. One that cannot explain its own data-sharing practices is a risk.
10. What Does Long-Term Treatment Look Like Here?
A 2021 study in JAMA Psychiatry tracking 5,600 patients across multiple outpatient MAT programs found that each additional month of treatment was associated with a measurable reduction in relapse risk, with the most significant protective effect observed in patients who remained in treatment beyond 12 months. The clinical consensus from multiple professional bodies, including ASAM and SAMHSA, is that MAT duration should be individualized and clinically guided, not calendar-driven.
Programs that push for rapid taper within 30 to 90 days are not operating consistently with this evidence. The impulse to “get off the medication as fast as possible” is understandable from a lay perspective but misunderstands the nature of opioid use disorder as a chronic condition. Cardiovascular disease patients are not pressured to taper off antihypertensives within three months. The same logic applies here.
Ask the provider what percentage of their patients are still in treatment at 12 months. Ask what the clinic’s average treatment duration looks like, and what the clinical rationale is for their standard taper timeline. A provider who speaks about taper as a process guided by individual patient stability, not by a fixed schedule, is working from the right framework. A provider who describes standard 60-day or 90-day programs without clinical justification deserves a follow-up question.
11. Do You Offer Any Support Beyond the Appointment?
A 2022 NIDA-funded study tracking 800 patients across five outpatient MAT programs found that peer recovery support services, including between-visit check-ins and peer coach availability, were associated with a 23 percent improvement in 90-day retention compared to medication management alone. The mechanism is simple: most crises happen between appointments, not during them.
Cravings, social pressure, and high-risk situations do not schedule themselves for Tuesday at 2 p.m. A program that is only accessible during office hours leaves a significant gap in the care continuum. The strongest programs have defined protocols for what happens when a patient is struggling at 10 p.m. on a weekend: a crisis line, a peer coach, a next-day callback from a clinician, something more than a voicemail box.
The concrete action: ask the provider exactly what the procedure is for a patient experiencing a craving emergency outside of office hours. The specificity of the answer tells you more than the content. A vague answer about “resources being available” is not a protocol. A clear description of a crisis contact number, peer support access, or on-call clinician availability is. Programs that have thought carefully about between-visit support have usually built it because experience taught them they had to.
12. Can You Tell Me About Your Patient Outcomes?
This is the question most patients don’t ask, and it is the one that separates programs running on reputation from programs running on evidence. CMS quality measure frameworks and SAMHSA reporting guidelines both identify specific outcome benchmarks for MAT programs, including 6-month retention rates, rates of negative urine screens at 6 months, and treatment completion rates. Programs that track these metrics and can discuss them have a fundamentally different relationship to their own clinical performance than programs that cannot.
A 2022 analysis of publicly reported quality data from opioid treatment programs found that programs with above-average transparency about patient outcomes also tended to have above-average retention rates. The correlation is not coincidental. Programs that know their numbers and report them honestly are also typically the ones investing in the clinical infrastructure that produces good numbers.
Ask the provider for their 6-month retention rate. For context: SAMHSA’s benchmark for outpatient MAT retention at 6 months is approximately 40 to 50 percent for community-based programs, with high-performing programs reaching 60 percent or higher. A provider who cannot or will not share this figure is offering anecdote, not evidence. Treat that as a non-negotiable data point. Understanding what accreditation and outcome accountability look like in a well-run program gives you an additional reference point when evaluating what you hear.
What to Do With These Answers
Bring this list to the first phone call, not just the first in-person appointment. Most of these questions can and should be answered before you ever walk through a door. A clinic’s willingness to answer them directly, without deflecting to intake paperwork or “we’ll go over that when you come in,” is itself a signal about how that clinic operates.
Evasive answers are data. A provider who hedges on relapse policy, cannot explain their dosing rationale, or deflects questions about credentials is telling you something about how clinical decisions get made inside that program. You are not being difficult by asking. You are doing exactly what a patient making a high-stakes healthcare decision should do.
Two practical notes on format: you do not need to ask all 12 questions in a single call. Prioritize three or four based on what matters most to your situation. And take notes. You may speak with two or three providers before choosing one, and the differences in how they answer these questions will become your clearest basis for comparison.
If you start with one question today, start with Question 4: how long between first contact and first prescription? The evidence on intake speed and treatment entry is among the strongest in the addiction medicine literature. A program that has optimized for rapid entry has usually also thought hard about the other parts of this list. One that hasn’t is likely to have gaps elsewhere. That single answer gives you a lot of signal about the rest.
The difference between programs that retain patients and programs that don’t often comes down to exactly the details these questions surface: whether the clinic operates with the flexibility, accountability, and clinical depth that independent programs built around long-term patient relationships tend to prioritize over those running on volume and standardized protocols. The questions above give you a framework for seeing that difference clearly before you commit.